Payment overview · 2025
General Payments
$7,367.78
15 reported records · 10 companies
Healthcare provider profile · identity verified
William J Feeney, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LATHAM, NY · NPI 1336146364
Verified facts
What the public records show
CMS Open Payments records show William J Feeney, MD received $7,367.78 in general payments during 2025 across 15 reported records.
Renalytix AI, Inc. accounted for 97.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $7,150.70 | 97.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.66 | 0.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.00 | 0.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.33 | 0.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.74 | 0.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.34 | 0.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.16 | 0.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.04 | 0.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.96 | 0.2% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $13.85 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $7,140.00 | 3 |
| Food and Beverage | $227.78 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $7,150.70 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $61.66 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 503 | 163 |
| Famotidine | Famotidine | 251 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 64 |
| Lisinopril | Lisinopril | 220 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 68 |
| Metformin Hcl Er | Metformin Hcl | 187 | 59 |
| Omeprazole | Omeprazole | 185 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 36 |
| Losartan Potassium | Losartan Potassium | 110 | 39 |
| Ozempic | Semaglutide | 104 | 22 |
| Celecoxib | Celecoxib | 94 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 26 |
| Gabapentin | Gabapentin | 86 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 25 |
| Trazodone Hcl | Trazodone Hcl | 75 | 18 |
| Irbesartan | Irbesartan | 68 | 20 |
| Alendronate Sodium | Alendronate Sodium | 66 | 23 |
| Farxiga | Dapagliflozin Propanediol | 65 | 20 |
| Sertraline Hcl | Sertraline Hcl | 64 | 21 |
| Alprazolam | Alprazolam | 62 | 17 |
| Allopurinol | Allopurinol | 58 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 14 |
| Finasteride | Finasteride | 54 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 15 |
| Clonazepam | Clonazepam | 51 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 16 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Simvastatin | Simvastatin | 41 | 13 |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Buprenorphine | Buprenorphine | 40 | suppressed |
| Valsartan | Valsartan | 40 | 13 |
| Jardiance | Empagliflozin | 38 | 11 |
| Tramadol Hcl | Tramadol Hcl | 37 | 12 |
| Montelukast Sodium | Montelukast Sodium | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Eliquis | Apixaban | 31 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 28 |
| Carvedilol | Carvedilol | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Azithromycin | Azithromycin | 25 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 14 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 19 |
| Furosemide | Furosemide | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 19 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Metformin Hcl | Metformin Hcl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Prednisone | Prednisone | 18 | 14 |
| Colchicine | Colchicine | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Otezla | Apremilast | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,367.78 · 15 records | Renalytix AI, Inc. | AIRSUPRA, EVENITY, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, LEQVIO, MOUNJARO, NURTEC ODT, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error